Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a structurally distinct M4 Positive Allosteric Modulator.
NMRA-898 is the second M4 PAM in Neumora's M4 franchise, with both programs showing potential best-in-class pharmacology. Pre-clinical studies conducted in multiple species, including rabbits, did not observe convulsions.
- NMRA-898 is structurally distinct from NMRA-861.
- No convulsions observed in pre-clinical studies.
No additional information is available at this time.
Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
Author's summary: Neumora starts Phase 1 study of NMRA-898.
More News
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists
- CRC Screening Improvements Decrease Mortality, but Disparities Persist
- John Cleese's European tour documentary to be shown at Clacton cinema
- Disparities in PsA Burden and Treatment Linked to Geographic and Social Factors
- The environmental impact of the 2026 World Cup
- Weather forecast for this week in Frome - 27 Oct to 2 Nov
- The new age of pediatric medication awareness - Express Healthcare
- Canada’s Lululemon Partners With National Football League
- Racial Disparities Persist in Victim Compensation for Homicide Survivors
- Elon Musk could step down if Tesla pay plan is rejected